Cambridge, UK, 15 May 2006 – BioProgress (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, today announced that its treatment for sore throats, Collunovar, has been launched in France as an over-the-counter (OTC) medicine.   

The product has previously been marketed only to doctors for prescription use. The change of status will increase the market potential for the product with the ability to launch new line extensions. 

Collunovar is one of the brands acquired by BioProgress with the acquisition of Dexo in January 2006. It is a product that contains the molecule Chlorhexidine which acts as a local antibacterial agent in the mouth. It can be used for the treatment of sore throats and other oral conditions such as gingivitis.  

With Collunovar as an OTC medicine, Dexo France plans to build a core franchise in the cough and cold category using a long established brand with good prescription heritage. BioProgress plans to develop new line extensions using the Company’s XGEL™ polymer technologies.  

Dexo has also extended its agreement with the pharmaceutical sales and marketing company, Cristers, to incorporate Collunovar. The Company expects this extension to help maximise the sales of the product to retail pharmacies before the traditional buy-in period for the cough and cold season. 

Richard Trevillion, CEO of BioProgress said: “Collunovar is an important strategic product for our Dexo subsidiary. By delivering a well known brand into the OTC arena Collunovar will not only deliver short term organic growth, but more importantly, it will serve as a core brand to launch a number of other products in the market sector using our technology. Our ongoing confidence with the Cristers management has allowed us to accelerate our OTC ambitions in France. The launch highlights our proactive management in creating revenue growth for our shareholders” 

BioProgress is currently developing a number of reformulated products using a variety of the Group’s platform technologies, including TABWRAP™, SWOLLO™ and WAFERTAB™, and based on existing branded and generic formulations. 

For further information please contact: 

BioProgress plc	+44 (0)1223 394250
Richard Trevillion, Chief Executive Officer
Northbank Communications	+44 (0)207 886 8150
Sue Charles Gemma Bradley Justine Lamond

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London’s AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com 

About Cristers:

Cristers is a pharmaceutical sales and marketing company with over 160 sales based personnel based in Herblay, near Paris in France. The company was formed in 2005 by Stephane Joly, President of Cristers, with the backing of Investinov and Nepenthes. Investinov is France’s leading Contract Sales Organisation with over 1200 medical representatives. Nepenthes is one of France’s largest retail pharmacist buying groups with over 22% market share.  

Forward-Looking Information. 

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934.  To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may vary materially from the expectations contained in the forward-looking statements.  The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation.  Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company’s filings with the Securities and Exchange Commission.  The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.  This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice.  The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law.  Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. 

-ENDS-